People · Operator
Named in public records as an officer, director or promoter · active 2012–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Semma Therapeutics, Inc. | — | Biotechnology | Series D+ | $129.3M | $4.7B | 2017 |
| Vascular Pharmaceuticals, Inc. | — | Biotechnology | Series B | $47.3M | $119.1M | 2012 |
Elizabeth Stoner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elizabeth Stoner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Todd Foley | 1 | 12 |
| STEPHEN KNIGHT | 1 | 6 |
| Richard Shea | 1 | 5 |
| Richard Kent | 1 | 5 |
| Kevin Raidy | 1 | 4 |
| Ken Williams | 1 | 3 |
| Daniel Auerbach | 1 | 3 |
| MARK FISHMAN | 1 | 3 |
| Robert Millman | 1 | 3 |
| Vaughn Kailian | 1 | 3 |
| Mitchell Finer | 1 | 3 |
| Benjamin Rovinski | 1 | 3 |
| Bastiano Sanna | 1 | 2 |
| Jim Scopa | 1 | 2 |
| Mitch Finer | 1 | 2 |
| William Sahlman | 1 | 2 |
| Bonnie Layman | 1 | 1 |
| Kingsley Taft | 1 | 1 |
| David Clemmons | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.